194 related articles for article (PubMed ID: 32158639)
1. Belatacept and CD28 Costimulation Blockade: Preventing and Reducing Alloantibodies over the Long Term.
Parsons RF; Larsen CP; Pearson TC; Badell IR
Curr Transplant Rep; 2019 Dec; 6(4):277-284. PubMed ID: 32158639
[TBL] [Abstract][Full Text] [Related]
2. Superior inhibition of alloantibody responses with selective CD28 blockade is CTLA-4 dependent and T follicular helper cell specific.
La Muraglia GM; Zeng S; Crichton ES; Wagener ME; Ford ML; Badell IR
Am J Transplant; 2021 Jan; 21(1):73-86. PubMed ID: 32406182
[TBL] [Abstract][Full Text] [Related]
3. Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig.
Badell IR; La Muraglia GM; Liu D; Wagener ME; Ding G; Ford ML
Am J Transplant; 2018 Jan; 18(1):89-101. PubMed ID: 28637095
[TBL] [Abstract][Full Text] [Related]
4. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.
Leibler C; Thiolat A; Hénique C; Samson C; Pilon C; Tamagne M; Pirenne F; Vingert B; Cohen JL; Grimbert P
J Am Soc Nephrol; 2018 Mar; 29(3):1049-1062. PubMed ID: 29321143
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.
Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS
Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566
[TBL] [Abstract][Full Text] [Related]
6. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.
Cvetkovski F; Razavi R; Sellberg F; Berglund E; Berglund D
Am J Transplant; 2023 Oct; 23(10):1603-1611. PubMed ID: 37270108
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
[TBL] [Abstract][Full Text] [Related]
8. Increased Pretransplant Frequency of CD28
Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
[TBL] [Abstract][Full Text] [Related]
9. Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion.
Habib JG; Liu D; Crepeau RM; Wagener ME; Ford ML
Front Immunol; 2022; 13():1081163. PubMed ID: 36761170
[TBL] [Abstract][Full Text] [Related]
10. CD28-Selective Inhibition Prolongs Non-Human Primate Kidney Transplant Survival.
Lovasik BP; Kim SC; Higginbotham L; Wakwe W; Mathews DV; Breeden C; Farris AB; Larsen CP; Ford ML; Nadler S; Adams AB
bioRxiv; 2023 May; ():. PubMed ID: 37205571
[TBL] [Abstract][Full Text] [Related]
11. A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation.
Lo DJ; Anderson DJ; Song M; Leopardi F; Farris AB; Strobert E; Chapin S; Devens B; Karrer E; Kirk AD
Am J Transplant; 2015 Apr; 15(4):984-92. PubMed ID: 25703015
[TBL] [Abstract][Full Text] [Related]
12. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.
Gardner D; Jeffery LE; Sansom DM
Am J Transplant; 2014 Sep; 14(9):1985-91. PubMed ID: 25098238
[TBL] [Abstract][Full Text] [Related]
13. Selective Costimulation Blockade With Antagonist Anti-CD28 Therapeutics in Transplantation.
Vanhove B; Poirier N; Soulillou JP; Blancho G
Transplantation; 2019 Sep; 103(9):1783-1789. PubMed ID: 30951014
[TBL] [Abstract][Full Text] [Related]
14. Impact of selective CD28 blockade on virus-specific immunity to a murine Epstein-Barr virus homolog.
Crepeau RL; Elengickal JA; La Muraglia GM; Ford ML
Am J Transplant; 2019 Aug; 19(8):2199-2209. PubMed ID: 30801917
[TBL] [Abstract][Full Text] [Related]
15. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
[TBL] [Abstract][Full Text] [Related]
16. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Latek R; Fleener C; Lamian V; Kulbokas E; Davis PM; Suchard SJ; Curran M; Vincenti F; Townsend R
Transplantation; 2009 Mar; 87(6):926-33. PubMed ID: 19300198
[TBL] [Abstract][Full Text] [Related]
17. Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
Ville S; Poirier N; Blancho G; Vanhove B
Front Immunol; 2015; 6():411. PubMed ID: 26322044
[TBL] [Abstract][Full Text] [Related]
18. Belatacept-Resistant Rejection Is Associated With CD28
Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
[TBL] [Abstract][Full Text] [Related]
19. Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.
Liu D; Badell IR; Ford ML
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321374
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
